Sign inJoin free

Watch / CEOs & MDs

Closer to a hard launch

25 July 20245:34

Closer to a hard launch

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Lee Rodney, Chairman of LTR Pharma (ASX: LTP), shares about the company's recent achievement of a $10.5 million share placement to sophisticated and institutional investors. The aim is to speed up the commercialisation of Swanton, a novel treatment for erectile dysfunction. He indicates the enthusiastic support received from institutional investors as a significant step, following the company's successful IPO last December, and the encouraging data for this fast-acting Viagra-like product.

Lee highlights the unique selling propositions of Swanton, emphasising the faster onset of action and its safety profile compared to conventional tablets. The administration via nasal spray innovation allows it to bypass the digestive route, thus reducing common unpleasant side effects. This efficiency enables it to use half the dosage of comparable tablets on the market, indicating an improved safety profile. The focus in the following quarters would be the onboarding of new doctor groups and expanding online sales channels, particularly through men’s health websites.

Despite not being able to predict market reaction, Lee conveys a sense of optimism for the future. He envisions high demand for such a fast-acting treatment, in view of the growing prevalence of erectile dysfunction globally. The company's focus is to make the product widely available in Australia by year end, with confidence supported by successful clinical study outcomes and positive share price performance since their listing.

Full unedited transcript below:

0:00

Let's move on to small cap news. Little farmer. Just completing a $10.5 million share placement to sophisticated and new institutional investors. The goal now to successfully commercialize Swanton, which is a new form of treatment for erectile dysfunction. To tell me more about the company's project. Lee Rodney, chairman of LTR Pharma, joins me now. Lee, we've spoken a few times what's changed? Tell us about this share placement and what it will achieve.

0:27

It's a great sign that we've had that support from institutional investors now. So we've really kicked some goals and some milestones since our IPO in December. Uh, we've released, uh, very, very strong data. We believe some of the best data in the world for a fast acting Viagra like product. So, uh, that can work within ten minutes. And, and that really fits, uh, a very high unmet need in the marketplace. So what will, I guess, this capital injection really achieve? It's just going to bring it to market sooner. Is that correct? Yeah. So it's really going to accelerate our commercial commercialization process. So uh, we expect uh, key doctors, so top doctors in Australia to start prescribing, uh, our nasal spray in the coming quarter. Uh, so increased, uh, you know, production, uh, really focusing on a direct to consumer website, uh, build out because a lot of these drugs is Viagra like drugs are going online now. So online sales channel through through, uh, um through men's health websites for instance, like men can get prescribed and are diagnosed and and prescribed with these types

1:26

of products all online now. Um, so helping us to tap into that online sales channels key over the next 3 to 6 months for us. Uh, and then, you know, partnering in licensing discussions. So a lot of global pharmaceutical companies that are interested in this erectile dysfunction space, um, are watching us now and, and watching and how we, we get, uh, commercialization completed over the next 3 to 6 months. So you talk about the rapid onset. What about the safety piece? How much safer this potentially is than a pill form? Well, there's two, two, uh, facets to that. So the tablets themselves, they have to go through the stomach and the liver, uh, before they get to the bloodstream. So those are the traditional treatments right now, uh, like Viagra and and those are really rough on the stomach and the lining of the and the liver, uh, to go through, uh, for those tablets. So men get uh, adverse reactions to, to those, they get stomach aches, they get, uh, you know, other unpleasant, uh, items like diarrhea, etc.. Uh, when, when tablets

2:26

go through that, uh, that digestive system, our technology, our IP technology goes to the nasal cavities. So we bypass that digestive route. So it's much more efficient, uh, processing, uh, into the bloodstream. And, and because of that, uh, we're able to use half the dosage than the comparable tablets on markets. So, uh, we do expect a much more improved, uh, safety profile. And certainly that's what we've seen in our clinical studies. So the $10.5 million raise really does reflect, I guess, the confidence in this spray. When do you expect it will come to market? When can it be readily available? Yeah, so we're focused initially in the coming quarter with the top doctors. These are doctors who are very well published in Men's Health and erectile Dysfunction. Uh, they they go around, you know, globally and speak at international conferences and about new technologies and new products in this sector. So we're really focused on getting our product in the hands of, of those doctors initially to start prescribing. And then we'll we'll be onboarding new doctor groups, uh,

3:26

in the coming quarters. So we expect widely available in Australia uh, towards the end of this year. So who's been involved in this studies. How are you sort of um, facilitating all of this? Lee.

3:38

Yeah. So we did the study in Sydney. Uh, and, uh, it was an FDA, uh, you know, under TGA guidance, uh, study. Um, and it was with, uh, a group of healthy, healthy volunteers where we're able to show, uh, the time that it takes to get, uh, our drug through the nasal spray into the bloodstream compared to the tablets. So that's what's called the, uh, you know, uh, pivotal, uh, um, pharmacology, pharmacokinetic, dynamic, uh, study. And so we're able to show that our drug gets into the bloodstream within ten minutes, uh, versus, uh, the oral tablets get into the bloodstream on average of 56 minutes, but the longest for the tablets was 2.5 hours. So really, you know, we're giving men in their partners the ability to live in the moment. And and as for an on demand type of treatment for erectile dysfunction, that can work within ten minutes versus needing to wait up to 2.5 hours in some cases. And as we've talked about, I mean, obviously, the confidence in the drug given

4:38

the capital raising, but also what you've seen reflected in your share price since listing When Spondon does come to market, what would you expect to see in terms of reaction? I can't control the market. It's going to be exciting, you know, for, uh, for all the, the men, uh, that have experienced the, you know, in Australia but also globally. So we anticipated being picked up globally that that news flow as, as it comes to market here in Australia. So it's, uh, once you reach the age of 45 years of age in, in, uh, uh, you know, globally, as a male, uh, 60% of men suffer from erectile dysfunction. Uh, and that's just growing. So other medications, you know, we've seen an explosion of other drugs, like in weight loss drugs come on the market. And and even those types of drugs lead to more incidence in a higher incidence rate of, uh, of erectile dysfunction. So this market is only growing. And the the market need for a fast acting on demand product is just growing. So we're quite excited about it.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy